When Cold Is Hot: Immune Checkpoint Inhibition Therapy for Rhabdoid Tumors

Area of Science:

• Oncology
• Immunology
• Cancer Genomics

Background:

• Carcinogen-induced cancers often have high mutation burdens and inflamed microenvironments, making them responsive to immune checkpoint inhibitors (ICIs).
• The SWI/SNF complex plays a crucial role in DNA repair and chromatin remodeling, and its dysfunction is implicated in various cancers.

Purpose of the Study:

• To investigate the potential response of cancers with SWI/SNF complex mutations to immune checkpoint inhibitor (ICI) therapy.
• To understand the immunophenotype of SWI/SNF-mutated cancers in the context of ICI treatment.

Main Methods:

• Analysis of cancer mutation burdens.
• Assessment of the tumor microenvironment's inflammatory status.
• Correlation of SWI/SNF mutation status with ICI response.

Main Results:

• Cancers with SWI/SNF loss-of-function mutations exhibit an inflamed immunophenotype.
• Despite having fewer mutations compared to carcinogen-induced cancers, these tumors are predicted to respond to ICI therapy.

Conclusions:

• SWI/SNF-mutated cancers possess an inflamed tumor microenvironment that may sensitize them to immune checkpoint inhibitors.
• These findings suggest a potential therapeutic strategy using ICIs for patients with SWI/SNF-deficient tumors.